GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xintela AB (FRA:1XT) » Definitions » EV-to-FCF

Xintela AB (FRA:1XT) EV-to-FCF : -15.43 (As of Apr. 04, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Xintela AB EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Xintela AB's Enterprise Value is €24.51 Mil. Xintela AB's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was €-1.59 Mil. Therefore, Xintela AB's EV-to-FCF for today is -15.43.

The historical rank and industry rank for Xintela AB's EV-to-FCF or its related term are showing as below:

FRA:1XT' s EV-to-FCF Range Over the Past 10 Years
Min: -18.94   Med: -2.84   Max: -0.24
Current: -16.09

During the past 11 years, the highest EV-to-FCF of Xintela AB was -0.24. The lowest was -18.94. And the median was -2.84.

FRA:1XT's EV-to-FCF is ranked worse than
100% of 440 companies
in the Biotechnology industry
Industry Median: 2.895 vs FRA:1XT: -16.09

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-04-04), Xintela AB's stock price is €0.0256. Xintela AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was €-0.007. Therefore, Xintela AB's PE Ratio (TTM) for today is At Loss.


Xintela AB EV-to-FCF Historical Data

The historical data trend for Xintela AB's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xintela AB EV-to-FCF Chart

Xintela AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.04 -10.27 -4.37 -1.94 -2.74

Xintela AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.12 -2.74 -3.84 -3.23 -15.26

Competitive Comparison of Xintela AB's EV-to-FCF

For the Biotechnology subindustry, Xintela AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xintela AB's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xintela AB's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Xintela AB's EV-to-FCF falls into.


;
;

Xintela AB EV-to-FCF Calculation

Xintela AB's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=24.510/-1.588
=-15.43

Xintela AB's current Enterprise Value is €24.51 Mil.
Xintela AB's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.59 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Xintela AB  (FRA:1XT) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Xintela AB's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.0256/-0.007
=At Loss

Xintela AB's share price for today is €0.0256.
Xintela AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.007.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Xintela AB EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Xintela AB's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Xintela AB Business Description

Traded in Other Exchanges
Address
Medicon Village, Lund, SWE, 22381
Xintela AB is a biomedical company that develops stem cell-based treatments with a focus on osteoarthritis and hard-to-heal leg wounds as well as, through the wholly-owned subsidiary Targinta, targeted antibody-based treatments for aggressive cancers such as triple-negative breast cancer and the brain tumor glioblastoma.

Xintela AB Headlines

No Headlines